JPWO2020074902A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020074902A5 JPWO2020074902A5 JP2021519114A JP2021519114A JPWO2020074902A5 JP WO2020074902 A5 JPWO2020074902 A5 JP WO2020074902A5 JP 2021519114 A JP2021519114 A JP 2021519114A JP 2021519114 A JP2021519114 A JP 2021519114A JP WO2020074902 A5 JPWO2020074902 A5 JP WO2020074902A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- virus vector
- scr4
- scr3
- scr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700618 Vaccinia virus Species 0.000 claims 18
- 239000013598 vector Substances 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 claims 3
- 101000668170 Homo sapiens RNA-binding motif, single-stranded-interacting protein 2 Proteins 0.000 claims 3
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 claims 3
- 102100039690 RNA-binding motif, single-stranded-interacting protein 2 Human genes 0.000 claims 3
- 101150105073 SCR1 gene Proteins 0.000 claims 3
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 101150035509 N1L gene Proteins 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- -1 antibodies Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816547.2A GB201816547D0 (en) | 2018-10-10 | 2018-10-10 | Oncolytic virus for the treatment of cancer |
| GB1816547.2 | 2018-10-10 | ||
| PCT/GB2019/052877 WO2020074902A1 (en) | 2018-10-10 | 2019-10-10 | Oncolytic vaccinia virus with modified b5r gene for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502066A JP2022502066A (ja) | 2022-01-11 |
| JPWO2020074902A5 true JPWO2020074902A5 (enExample) | 2022-10-04 |
| JP7410139B2 JP7410139B2 (ja) | 2024-01-09 |
Family
ID=64397608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519114A Active JP7410139B2 (ja) | 2018-10-10 | 2019-10-10 | 癌治療のための修飾ｂ５ｒ遺伝子を有する腫瘍溶解性ワクシニアウイルス |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3863669A1 (enExample) |
| JP (1) | JP7410139B2 (enExample) |
| KR (1) | KR20210102196A (enExample) |
| CN (1) | CN113453713A (enExample) |
| CA (1) | CA3123973A1 (enExample) |
| GB (1) | GB201816547D0 (enExample) |
| WO (1) | WO2020074902A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4561599A1 (en) * | 2022-07-27 | 2025-06-04 | Astrazeneca AB | Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201405834D0 (en) * | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| US10888594B2 (en) * | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| TW201825674A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
-
2018
- 2018-10-10 GB GBGB1816547.2A patent/GB201816547D0/en not_active Ceased
-
2019
- 2019-10-10 JP JP2021519114A patent/JP7410139B2/ja active Active
- 2019-10-10 EP EP19794623.9A patent/EP3863669A1/en active Pending
- 2019-10-10 CN CN201980081698.5A patent/CN113453713A/zh active Pending
- 2019-10-10 CA CA3123973A patent/CA3123973A1/en active Pending
- 2019-10-10 KR KR1020217013839A patent/KR20210102196A/ko active Pending
- 2019-10-10 WO PCT/GB2019/052877 patent/WO2020074902A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101114784B1 (ko) | 아데노바이러스 벡터 백신 | |
| JP4472250B2 (ja) | 高発現可能遺伝子 | |
| Kirk et al. | T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy | |
| Fakhrai et al. | Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. | |
| Bermúdez-Humarán et al. | Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production | |
| Pasquini et al. | Cytokines and costimulatory molecules as genetic adjuvants | |
| JP2006141398A5 (enExample) | ||
| JP2025023916A5 (enExample) | ||
| US8293252B2 (en) | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization | |
| Xiang et al. | The effect of interferon-γ on genetic immunization | |
| JPWO2019173798A5 (enExample) | ||
| Lui et al. | Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor | |
| Ma et al. | Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells | |
| JPWO2020074902A5 (enExample) | ||
| JP4719876B2 (ja) | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド | |
| JPWO2020124274A5 (enExample) | ||
| KR100788930B1 (ko) | 항암 조성물 | |
| CZ20011521A3 (cs) | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek | |
| US20220213160A1 (en) | Protein heterodimer and use thereof | |
| Frauenschuh et al. | Differential polarization of immune responses by co-administration of antigens with chemokines | |
| Rollman et al. | HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses | |
| EP0546099B1 (en) | Use of human Interferon gamma 4-134 | |
| JPWO2020188348A5 (enExample) | ||
| AU2021236879A1 (en) | A mixture of mRNA to enhance the potency of dendritic cells | |
| Sfondrini et al. | Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice |